Dr. Payal Kohli and Dr. C. Michael Gibson Discuss: Deep Dive on Prevention Trials at AHA 2022 November 7, 2022 Disclosures: TBD
Dr. Julia Grapsa and Dr. C. Michael Gibson Discuss: AHA 2022 ACCess Points Daily Wrap-Up – November 5, 2022 November 7, 2022 Disclosures: TBD
Dr. Cian McCarthy and Dr. C. Michael Gibson Discuss: Implementation of High-Sensitivity Cardiac Troponin Assays in the United States November 7, 2022 Disclosures: TBD
Dr. Steve Nissen, Dr. Luke Laffin, and Dr. C. Michael Gibson Discuss: Comparative Effects of Low-Dose Rosuvastatin, Placebo and Dietary Supplements on Lipids and Inflammatory Biomarkers November 7, 2022 Disclosures: TBD
Dr. James Jollis, Dr. Jacqueline Tamis-Holland, and Dr. C. Michael Gibson Discuss: Treatment Time and In-Hospital Mortality Among Patients With ST-Segment Elevation Myocardial Infarction, 2018-2021 November 7, 2022 Disclosures: TBD
Dr. Jonathan Piccini and Dr. C. Michael Gibson Discuss: NOVA – Efficacy and Safety of Botulinum Toxin Type A for the Prevention of Postoperative Atrial Fibrillation in Cardiac Surgery Patients: Results from the Phase 2 Nova Study November 7, 2022 Disclosures: TBD
Dr. Matthew Budoff and Dr. C. Michael Gibson Discuss: STOP – Effect of Semaglutide on Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes: Final Results of the Stop Study November 7, 2022 Disclosures: TBA
Dr. Hyo Soo Kim and Dr. C. Michael Gibson Discuss: HOST-EXAM – Long Term Follow-Up of Aspirin vs. Clopidogrel Monotherapy in the Chronic Maintenance Period After Percutaneous Coronary Intervention: The Host-Exam Extended Study November 7, 2022 Disclosures: TBD
Dr. Erlend Berg and Dr. C. Michael Gibson Discuss: After Eighty Study – Long-Term Outcomes of an Invasive versus Conservative Strategy in Stabilised Patients Aged 80 Years or Older With Non-ST-Elevation Acute Coronary Syndrome, After Eighty Study: A Randomised Controlled Trial November 7, 2022 Disclosures: TBD
Dr. Carolyn Lam and Dr. C. Michael Gibson Discuss: Heart Failure Trials at AHA 2022 November 6, 2022 Disclosures: TBD
